Details of the study methodology and the patient population have been described previously.2 In addition to the entry and follow-up forms, a separate form was designed for reporting newly developed inhibitors, with particular reference to events possibly relevant to inhibitor occurrence.
Reports were sent to the reference laboratory and the statistical center, and a plasma sample was forwarded to the reference laboratory for confirmation of the inhibitor. P-Series, 1979 . For some analyses, "usual" rather than entry factor VIIIC levels were used. The usual level took into account all basal factor VIII:C measurements on enrolled patients that were furnished by participating centers and provided a better separation of the patient groups with s0.03 and >0.03 U/mL factor VIII:C. This approach was specifically relevant to those patients whose reported basal factor VIII:C ranged from <0.01 to 0.03 U/mL. We attribute these fluctuations to within-patient variation at the interface of severe and moderate factor VIII:C deficiency because assays of factor VIII:C should accurately separate activities in this range. Patients with only a single entry factor VIII:C measurement were excluded from these analyses. Factor VIII antigen (factor VIII:Ag) was measured on frozen plasma samples that had been obtained at entry, before inhibitor appearance.
The technique used has been described previously,4 except that the standard curve was constructed by diluting the normal plasma with hemophilic plasma devoid of factor VIII:Ag cross-reacting material instead of with buffer. 
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